For instance, A-485, a CREBBP/EP300 inhibitor, has been reported to inhibit cell growth and tumor progression as well as alleviate idelalisib resistance in MCL, potentially by blocking the PI3K/AKT/mTOR and MAPK signaling pathways [87]. Here, AKT1 is linked to neoplasm.